Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2015 16:15 ET | Source: Mateon Therapeutics

OXiGENE Announces 2014 Financial Results Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., March 4, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report...
February 24, 2015 09:15 ET | Source: Mateon Therapeutics

OXiGENE Announces Presentation and Webcast at the 27th Annual ROTH Conference on March 11th

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, announced that Dai Chaplin,...
January 26, 2015 16:15 ET | Source: Mateon Therapeutics

OXiGENE Announces Presentation and Webcast at the 17th Annual BIO CEO & Investor Conference on February 10th

SOUTH SAN FRANCISCO, Calif., Jan. 26, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, announced that David...
November 20, 2014 08:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Preclinical Poster Presentation on OXi4503 at Upcoming American Society of Hematology Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that a poster presentation...
November 17, 2014 16:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Issuance of European Patent for OXi4503 in Acute Myeloid Leukemia and other Myeloid Malignancies

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the company has been...
November 12, 2014 16:00 ET | Source: Mateon Therapeutics

OXiGENE Reports Third Quarter 2014 Financial Results

- Positive Data from the Phase 2 GOG 186I Study in Ovarian Cancer Presented at Major Conference - - Two Phase 2 Fosbretabulin Studies Initiated in Ovarian and Gastrointestinal Neuroendocrine...
November 10, 2014 03:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer

- Subgroup Analysis of GOG 186I Study Shows Benefit in Difficult-to-Treat Platinum-Resistant Patients - - Detailed Results Presented at the International Gynecologic Cancer Society Meeting -...
October 22, 2014 09:15 ET | Source: Mateon Therapeutics

OXiGENE Announces Third Quarter 2014 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will hold a...
October 07, 2014 16:01 ET | Source: Mateon Therapeutics

OXiGENE Announces First Patient Enrolled in Phase 1b/2 Study of Fosbretabulin Combined With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the first patient has...
October 06, 2014 16:01 ET | Source: Mateon Therapeutics

OXiGENE Announces Presentation of Data From the Phase 2 GOG186I Study at the 15th Biennial Meeting of the International Gynecologic Cancer Society

SOUTH SAN FRANCISCO, Calif., Oct. 6, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the data from the...